新利18世界杯|新利18平台可以注销吗

Skip to content Skip to search Skip to footer Neurosurgery Open Menu Back Close Menu Search for: Search Close Search AboutAbout News Diversity, Equity &＃038; Inclusion Contact Us Giving PeoplePeople Clinical Faculty Research Faculty Affiliated Faculty Fellows Residents Advanced Practice Providers Administration Patient CarePatient Care Aneurysms/Vascular Brain Tumors Chiari Malformation / Syringomyelia Epilepsy Hydrocephalus Movement Disorders Pain Pediatrics Peripheral Nerve Spine ResearchResearch Laboratories Clinical TrialsClinical Trials Trials with Outpatient EnrollmentTrials with Outpatient Enrollment Outpatient – Pediatric Outpatient-Spine and Peripheral Nerve Outpatient – Epilepsy and Functional Outpatient-Vascular Outpatient-Oncology Trials with Inpatient EnrollmentTrials with Inpatient Enrollment Inpatient – Oncology Inpatient – Vascular Inpatient- Pediatric Inpatient-Spine and Peripheral Nerve NeurotechnologyNeurotechnology Center for Innovation in Neuroscience and Technology (CINT) NEURO360 EducationEducation Residency Program Fellowship ProgramsFellowship Programs Advanced Surgical Neuro-oncology Fellowship Endovascular Surgical Neuroradiology Fellowship Pediatric Neurosurgery Fellowship Neurosurgical Peripheral Nerve and Spine Fellowship Neurosurgical Complex Spine Fellowship Stereotactic, Functional and Epilepsy Surgery Fellowship Third-year Clerkship Diversity Sub-internship Funding Medical Student Research Opportunities Fourth-year Sub-internship Learning Environment Life Outside the Hospital Join Our Team AppointmentsAppointments Patient imaging Patient forms Open Search Inpatient-Spine and Peripheral Nerve PI: Ray Protocol ID: M16-077 Short study title: Elezanumab for Acute Traumatic Cervical SCI (AbbVie) Sponsor: AbbVie Pharmaceutical Short description: Multi-center, randomized, double-blinded, placebo-controlled study. Elezanumab is a monoclonal antibody to repulsive guidance molecule A (RGMa). RGMa is a potent inhibitor of neurite outgrowth and negatively impacts neuroplasticity after injury. Elezanumab may lead to neuroregeneration, neuroprotection, and promote neurorestoration. It has been shown to be neuroprotective and neurorestorative in several animal models of acute and chronic neurologic injury with long-term benefits observed with early administration after acute injury. No evidence of drug-related toxicity in animal studies and in Phase 1 clinical studies. Primary endpoint is upper extremity motor function. Labs will also be drawn for identification of biomarkers. Key eligibility criteria: Any sex, age 18 through 70 ASIA A or B with isolated acute, traumatic cervical spinal cord injury Neurologic level anywhere C4 through C7, consistent with MRI Drug must be administered within 24h of injury Excludes: penetrating injury, clinically significant abnormality on head CT, immobilized upper extremity(s), COVID-19 infection within 14 days of screening, pregnancy Contact person: Linda Koester, 314-362-7368 Enrollment period: September 6th 2020 &＃8211; April 1st, 2022 For more information: https://clinicaltrials.gov/ct2/show/NCT04295538 PI: Ray Protocol ID: MT-3291-A01 Short study title: MT-3291 for Acute Traumatic Cervical SCI Sponsor: Mitsubishi Tanube Pharma Development America, Inc Short description: Phase 2a multi-center, randomized, double-blinded, placebo-controlled study. MT-3291 is a monoclonal antibody to the repulsive guidance molecule A (RGMa). RGMa is a potent inhibitor of neurite outgrowth and negatively impacts neuroplasticity after injury. MT-3291 may prevent inflammation, demyelination, and neurodegeneration. It has been shown to be neuroprotective and neurorestorative in several animal models (rats and monkeys) of acute and chronic neurologic injury with long-term motor benefits observed with early administration after acute injury. No evidence of drug-related toxicity in animal studies and in human studies (Japan, 2019-2020). Primary endpoint is upper extremity motor function. Serum and/or CSF (CSF at 1 week) will also be drawn for identification of biomarkers. Key eligibility criteria: Any sex, age 18 through 70 BMI < 40 ASIA A, B, or C with isolated acute, traumatic cervical spinal cord injury Neurologic level anywhere C4 through C7 If C4 level, must be at least 1/5 between C5 and C7 Must receive study drug/placebo within 48h of injury Excludes: penetrating injury, TBI with GCS < 14 (non-intubated) or GCS < 10 (intubated), immobilized upper extremity(s), significant polytrauma with ISS > 25, patients receiving steroids for purpose of SCI treatment, positive COVID-19 test, pregnancy Contact person: Linda Koester, 314-362-7368 Enrollment period: August 2021 &＃8211; January 2023 For more information: https://clinicaltrials.gov/ct2/show/NCT04683848 PI: Ray Protocol ID: HSC-MS-19-0258 Short study title: Discovery of Biomarkers Prognostic for Neuropathic Pain after Acute SCI (BSCIP) Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Short description: Multi-center observational study. It is not known why certain patients with SCI (40-70%) develop debilitating neuropathic pain while others are spared from this chronic condition. An autoimmune response can be triggered after SCI due to breakdown of the blood-spinal cord barrier leading to inflammation, hindering recovery, and promoting chronic pain. Discovering biomarker(s) predictive of neuropathic pain is important in developing safe and effective pain therapies. Several candidate antigens have been identified in animal models of SCI, but their relationship to human SCI is not known. The aim of this study is to identify serum autoantibodies in patients in the acute SCI setting that are prognostic for neuropathic pain 6 months after SCI when compared to healthy volunteers. Key eligibility criteria: Any sex, age 18 and up Acute traumatic ASIA A through D Serum collection within 24h of injury (OK to collect first then obtain consent) K2EDTA and sodium heparin tubes (Study team will supply the tubes for collection) Excludes: penetrating injury, TBI where patients cannot complete questionnaires and sensory testing, other chronic pain (i.e., diabetic neuropathy, MS), cancer diagnosis or treatment in last 5 years Contact person: Linda Koester, 314-362-7368 Enrollment period: September 1st, 2019 &＃8211; July 31st, 2022 For more information: https://reporter.nih.gov/project-details/9829265 PI: Ray Short study title: Repurposing Operating Room Specimens in Spine and Peripheral Nerve Surgery Short description: Human specimens are critical to studying nerve regeneration and neuropathic pain. Our previous work using primarily cadaver tissue has revealed important mechanisms behind pain and itch sensations. However, cadaver specimens are limited and are complicated by tissue degradation, which ultimately limits our understanding of the environments present in the human body. During spinal fusion and peripheral nerve surgeries, it is sometimes necessary to remove some or all of specific nerves or dorsal root ganglions (DRGs), which is usually discarded. This study proposes repurposing the otherwise discarded tissue for translational research purposes. Key eligibility criteria: Age 18 through 75 Patients scheduled to undergo any of the following spine procedures: C1-2 posterior instrumentation/fusion, posterior thoracic corpectomy (T3-T12), vertebral column resection Patients scheduled to undergo any of the following peripheral nerve procedures: nerve transfer, brachial plexus reconstruction, distal peripheral nerve reconstructions Excludes: patients with neurologic or psychiatric disorder that would preclude accurate evaluation (e.g., Parkinson’s disease, Alzheimer’s disease) Contact person: Linda Koester, 314-362-7368 or Alex Chamessian (Gereau Lab), 314-356-2270 Enrollment period: March 2021 &＃8211; Current PI: Ray/Molina  Protocol ID: 2021.01.10/1.2  Short study title: Intraspinal Pressure Monitoring for Acute Spinal Cord Injury  Short description: CSF diversion from the thecal sac after acute SCI using lumbar drain may provide benefits by relieving intraspinal pressure and improving spinal cord ischemia. This rationale is similar to the use of ventriculostomy catheters in acute hydrocephalus or TBI. Spinal cord perfusion pressure (SCPP) can be monitored and managed by using the intraspinal pressure (ISP) similar to how ICP and CPP are used. Preliminary studies have shown that ISP and SCPP during the first week of injury after SCI correlates with ASIA score at 9-12 months, and maintaining SCPP > 50mmHg correlated with a greater likelihood of patient recovery from baseline after injury. The goal of this study is to study the safety and outcomes of using lumbar drain after SCI in hopes of developing a management protocol. The aim is to keep the LD in place for 120 hours (5 days).  Key eligibility criteria:  Any sex, age 18 through 70  ASIA A through C  Surgery within 48 hours of SCI, LD to be placed immediately after surgery  If no surgery is indicated, LD to be placed within 24 hours of presentation  Ability to undergo reliable neurologic exams  Excludes: penetrating injury, pre-existing coagulopathy, evidence of increased ICP, skin infection at LD site  Contact person: Residents will take an active role in screening but should also notify Miguel Ruiz Cardozo, 314-827-9436, [email protected] Enrollment period: January 2021 – Current  PI: Ray and Molina Short study title: Augmedics XVision Surgical Navigation System Short description: A new technology, Augmedics XVision Surgical Navigation System, is a 3D augmented-reality headset that the surgeon wears in order to integrate all intraoperative imaging into a real-time stereoscopic 3D image of the patient’s anatomy. As such, it addresses the drawback of a surgeon needing to look away from the patient in order to view intraoperative imaging. Our previous cadaveric study demonstrated a 96.7% open and 98.9% percutaneous pedicle screw placement accuracy with Augmedics, which was shown to be non-inferior to robotic-assisted computer-navigated information and superior to conventional, fluoroscopically-guided manual placement of pedicle screw instrumentation. The aim of this study is to evaluate the accuracy of pedicle screw placement by the Augmedics XVision Surgical Navigation System and report on outcomes including pedicle wall breaches, radiologic degrees of deformity correction, complications, pain, cost, and patient satisfaction. Key eligibility criteria: Age 18 and up Patients scheduled to undergo spine surgery with pedicle screw insertion with the use of the XVS headset Patients will be enrolled at the discretion of the treating physician Enrollment period: June 2020 &＃8211; Current Clinical Trials Trials with Inpatient Enrollment Inpatient &＃8211; Oncology Inpatient &＃8211; Vascular Inpatient- Pediatric Inpatient-Spine and Peripheral Nerve Trials with Outpatient Enrollment Department of NeurosurgeryWashington University School of Medicine660 South Euclid AvenueCampus Box 8057St. Louis, MO 63110314-362-3570Contact Us Instagram Twitter YouTube Information Refer a patient Clinical faculty directory Locations Giving Careers Faculty job openings Staff job openings Patients MyChart Patient forms Patient imaging ©2024 Washington University in St. Louis